These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21838042)

  • 1. [Prevention of tuberculosis for the immunocompromised host with biological agents and corticosteroid].
    Miki M
    Nihon Rinsho; 2011 Aug; 69(8):1427-32. PubMed ID: 21838042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application and problems of quantiFERON TB-2G for tuberculosis control programs--(2) clinical use of quantiFERON TB-2G].
    Kawabe Y
    Kekkaku; 2007 Jan; 82(1):61-6. PubMed ID: 17310783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention of tuberculosis in immunocompromised patients].
    Perronne C
    Ann Med Interne (Paris); 1997; 148(3):226-9. PubMed ID: 9255330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis of mycobacterial infections in immunocompromised patients.
    Krance MB; Fisher MA
    Am Fam Physician; 1996 Nov; 54(6):1981-8, 1991-2. PubMed ID: 8900358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy.
    Mok MY; Lo Y; Chan TM; Wong WS; Lau CS
    J Rheumatol; 2005 Apr; 32(4):609-15. PubMed ID: 15801014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinical application of quantiferon TB-2G: its usefulness and limitations].
    Sato S; Nagai H
    Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Managing Mycobacterium tuberculosis infection and disease in patients with steroids or immunosuppressive drugs].
    Bahri F
    Rev Med Interne; 2009 Dec; 30 Suppl 4():S277-80. PubMed ID: 19896754
    [No Abstract]   [Full Text] [Related]  

  • 10. Tuberculosis in liver transplant patients.
    Meyers BR; Halpern M; Sheiner P; Mendelson MH; Neibart E; Miller C
    Transplantation; 1994 Aug; 58(3):301-6. PubMed ID: 8053051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay.
    Matulis G; Jüni P; Villiger PM; Gadola SD
    Ann Rheum Dis; 2008 Jan; 67(1):84-90. PubMed ID: 17644549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spectrum of tuberculosis infection: new perspectives in the era of biologics.
    Delogu G; Goletti D
    J Rheumatol Suppl; 2014 May; 91():11-6. PubMed ID: 24788995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
    Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R
    Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Latent tuberculosis infection: recommendations for preventive therapy in adults in Germany].
    Schaberg T; Hauer B; Haas WH; Hohlfeld J; Kropp R; Loddenkemper R; Loytved G; Magdorf K; Rieder HL; Sagebiel D
    Pneumologie; 2004 Apr; 58(4):255-70. PubMed ID: 15098162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.
    Aisu T; Raviglione MC; van Praag E; Eriki P; Narain JP; Barugahare L; Tembo G; McFarland D; Engwau FA
    AIDS; 1995 Mar; 9(3):267-73. PubMed ID: 7755915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemoprophylaxis for tuberculosis].
    Yamagishi F
    Kekkaku; 2005 Oct; 80(10):647-53. PubMed ID: 16296393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tuberculosis and anti-TNFalpha therapy].
    Popović-Grle S
    Reumatizam; 2007; 54(2):54-7. PubMed ID: 18351140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children.
    Bright-Thomas R; Nandwani S; Smith J; Morris JA; Ormerod LP
    Arch Dis Child; 2010 Aug; 95(8):600-2. PubMed ID: 20530147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world.
    Sterling TR; Brehm WT; Moore RD; Chaisson RE
    Int J Tuberc Lung Dis; 1999 Mar; 3(3):248-54. PubMed ID: 10094327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies.
    Keane J; Bresnihan B
    Curr Opin Rheumatol; 2008 Jul; 20(4):443-9. PubMed ID: 18525359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.